Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Preferred Stock Liabilities: 2022-2023

  • Lexeo Therapeutics' Preferred Stock Liabilities changed negligibly% to $185.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $185.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $185.0 million for FY2022, which is N/A change from last year.
  • As of Q3 2023, Lexeo Therapeutics' Preferred Stock Liabilities stood at $185.0 million, which was down 0.00% from $185.0 million recorded in Q4 2022.
  • Lexeo Therapeutics' Preferred Stock Liabilities' 5-year high stood at $185.0 million during Q3 2022, with a 5-year trough of $185.0 million in Q3 2022.
  • In the last 2 years, Lexeo Therapeutics' Preferred Stock Liabilities had a median value of $185.0 million in 2023 and averaged $185.0 million.